We have been watching the Darvocet multi-district litigation (MDL 2226) for some time, most notably the Sixth Circuit’s decision to dismiss 67 of 68 cases alleging misbranding by drug manufacturers. After that decision, plaintiffs’ counsel began filing new cases in California state court. The defendants removed the cases to federal court and then obtained a … Continue Reading
It’s been more than two years since we reported on the appeal in the Darvocet MDL (In re: Darvocet, Darvon and Propoxyphene Products Liability Litigation, No. 11-md-2226-DCR, MDL 2226), which involves claims against generic manufacturers of a generic equivalent of the drug Darvon. The biggest news is that the panel did not decide whether to … Continue Reading
